The treatment of epilepsy: Future possibilities

Drugs of the Future

Volumn 28, Issue 9, 2003, Pages 925-936

  Szelenyi, Istvan ^a   Horvath, Katalin ^b   Howes, John F ^c   Mazarati, Andrey M ^d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b TEVA PHARMACEUTICALS   (Israel)

^c IVAX Corporation   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLVALERAMIDE; 202 W92; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BACLOFEN; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GLUTAMIC ACID; ISOVALERAMIDE; LAMOTRIGINE; N METHYL TETRAMETHYLCYCLOPROPANE CARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; OXCARBAZEPINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; PREGABALIN; RILUZOLE; SIPATRIGINE; SPD 421; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALNOCTAMIDE; VALPROIC ACID DERIVATIVE; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; BRAIN PROTECTION; CLINICAL GENETICS; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EPILEPSY; EPILEPTOGENESIS; HUMAN; LIVER TOXICITY; MOLECULAR BIOLOGY; NEUROTRANSMISSION; NONHUMAN; REVIEW; SEIZURE; TERATOGENICITY;

EID: 0346363816     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.09.857380     Document Type: Review

References (137)

1. Bell, G.S., Sander, J.W. The epidemiology of epilepsy: The size of the problem. Seizure 2002, 11 (Suppl. A): 306-14.
2. Cowan, L.D. The epidemiology of the epilepsies in children. Ment Retard Dev Disabil Res Rev 2002, 8: 171-81.
3. Oun, A., Haldre, S., Magi, M. Prevalence of adult epilepsy in Estonia. Epilepsy Res 2003, 52: 233-42.
4. Begley, C.E., Lairson, D.R., Reynolds, T.F., Coan, S. Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res 2001, 47: 205-15.
5. Tetto, A., Manzoni, P., Millul, A. et al. The costs of epilepsy in Italy: A prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002, 48: 207-16.
6. Duncan, J.S. The promise of new antiepileptic drugs. Br J Clin Pharmacol 2002, 53: 123-31.
7. Backonja, M.M. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002, 59 (5, Suppl. 2): S14-7.
8. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P., Perucca, E. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001, 43: 11-58.
9. Hovinga, C.A. Novel anticonvulsant medications in development. Expert Opin Investig Drugs 2002, 11: 1387-406.
10. Löscher, W., Schmidt, D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002, 50: 3-16.
11. Selak, I. Pregabalin (Pfizer). Curr Opin Investig Drugs 2001, 2: 828-34.
12. Taylor, C.P., Vartanian, M.G., Yuen, P.W., Bigge, C., Suman-Chauhan, N., Hill, D.R. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res 1993, 14: 11-5.
13. Whitworth, T.L., Quick, M.W. Upregulation of gamma-aminobutyric acid transporter expression: Role of alkylated γ-aminobutyric acid derivatives. Biochem Soc Trans 2001, 29: 736-41.
14. Hurley, R.W., Chatterjea, D., Rose Feng, M., Taylor, C.P., Hammond, D.L. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology 2002, 97: 1263-73.
15. Huppertz, H.J., Feuerstein, T.J., Schulze-Bonhage, A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001, 42: 790-2.
16. A receptor. J Pharmacol Exp Ther 1997, 280: 1284-95.
17. Gasior, M., Carter, R.B., Goldberg, S.R., Witkin, J.M. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther 1997, 282: 543-53.
18. Gasior, M., Ungard, J.T., Beekman, M., Carter, R.B., Witkin, J.M. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: Comparison with diazepam and valproate. Neuropharmacology 2000, 39: 1184-96.
19. Snead, O.C. Ganaxolone, a selective, high-affinity steroid modulator of the γ-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol 1998, 44: 688-91.
20. Monaghan, E.P., Navalta, L.A., Shum, L., Ashbrook, D.W., Lee, D.A. Initial human experience with ganaxolone, a neuro-active steroid with antiepileptic activity. Epilepsia 1997, 38: 1026-31.
21. Reddy, D.S. Newer GABAergic agents for pharmacotherapy of infantile spasms. Drugs Today 2002, 38: 657-75.
22. B receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. Eur J Pharmacol 2001, 430: 251-9.
23. Czuczwar, S.J., Patsalos, P.N. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001, 15: 339-50.
24. Soudijn, W., van Wijngaarden, I. The GABA transporter and its inhibitors. Curr Med Chem 2000, 7: 1063-79.
25. Borden, L.A., Dhar, T.G., Smith, K.E., Branchek, T.A., Gluchowski, C., Weinshank, R.L. Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. Receptors Channels 1994, 2: 207-13.
26. Dalby, N.O. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 2000, 39: 2399-407.
27. Poisson, M., Huguet, F., Savattier, A., Bakri-Logeais, F., Narcisse, G. A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneim-Forsch Drug Res 1984, 34: 199-204.
28. Chiron, C., Marchand, M.C., Tran, A. et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356: 1638-42.
29. Tran, A., Rey, E., Pons, G. et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997, 62: 490-504.
30. Abel, M.S., Kohli, N. GABA-transaminase antisense oligodeoxynucleotide modulates cocaine- and pentylenetetrazol-induced seizures in mice. Metab Brain Dis 1999, 14: 253-63.
31. Karle, J. Antisense studies of brain GABAA receptors. Dan Med Bull 2002, 49: 130-44.
32. Jacoby, D.B., Lindberg, C., Cunningham, M.G., Ratliff, J., Dinsmore, J. Long-term survival of fetal porcine lateral ganglionic eminence cells in the hippocampus of rats. J Neurosci Res 1999, 56: 581-94.
33. Meldrum, B.S., Akbar, M.T., Chapman, A.G. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res 1999, 36: 189-204.
34. Toth, M., Tecott, L. Transgenic approaches to epilepsy. Adv Neurol 1999, 79: 291-6.
35. Calabresi, P., Centonze, D., Cupini, L.M., Costa, C., Pisani, F., Bernardi, G. Ionotropic glutamate receptors: Still a target for neuroprotection in brain ischemia? Insights from in vitro studies. Neurobiol Dis 2003, 12: 82-8.
36. Temkin, N.R., Jarell, A.D., Anderson G.D. Antiepileptogenic agents. Drugs 2001, 61: 1045-55.
37. Rubaj, A., Zgodzinski, W., Sieklucka-Dziuba, M. The epileptogenic effect of seizures induced by hypoxia: The role of NMDA and AMPA/KA antagonists. Pharmacol Biochem Behav 2003, 74: 303-11.
38. Stavem, K., Loge, J.H., Kaasa, S. Health status of people with epilepsy compared with a general reference population. Epilepsia 2000, 41: 85-90.
39. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P., Perucca, E. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002, 51: 31-71.
40. Gill, R., Alanine, A., Bourson, A., et al. Pharmacological characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 2002, 302: 940-8.
41. Rogawski, M.A., Yamaguchi, S., Jones, S.M., Rice, K.C., Thurkauf, A., Monn, J.A. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D-aspartate antagonist (±)-5-aminocarbonyl-10, 11-dihydro-5H-dibenzo[a, d]cyclohepten-5, 10-imine (ADCI): Comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. J Pharmacol Exp Ther 1991, 259: 30-7.
42. Rogawski, M.A., Le, D.Q., Uyakul, D. et al. Anticonvulsant efficacy of ADCI (5-aminocarbonyl-10, 11-dihydro-5H-dibenzo-[a,d]cyclohepten-5, 10-imine) after acute and chronic dosing in mice. Epilepsia 1995, 36: 566-71.
43. Coleman, M.H., Yamaguchi, S., Rogawski, M.A. Protection against dendrotoxin-induced clonic seizures in mice by anticonvulsant drugs. Brain Res 1992, 575: 138-42.
44. Sun, L., Lin, S.S. The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: Comparison with carbamazepine. Epilepsia 2000, 41: 263-70.
45. Prorok, M., Castellino, F.J. Structure-function relationships of the NMDA receptor antagonist conantokin peptides. Curr Drug Targets 2001, 2: 313-22.
46. Jimenez, E.C., Donevan, S., Walker, C. et al. Conantokin-L, a new NMDA receptor antagonist: Determinants for anticonvulsant potency. Epilepsy Res 2002, 51: 73-80.
47. Williams, A.J., Ling, G., McCabe, R.T., Tortella, F.C. Intrathecal CGX-1007 is neuroprotective in a rat model of focal cerebral ischemia. Neuroreport 2002, 13: 821-4.
48. 2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol 2000, 58: 614-23.
49. Mazarati, A.M., Sofia, R.D., Wasterlain, C.G. Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus. Seizure 2002, 11: 423-30.
50. Ohtani, K., Tanaka, H., Yoneda, Y. et al. In vitro and in vivo antagonistic activities of SM-31900 for the NMDA receptor glycine-binding site. Brain Res 2002, 944: 165-73.
51. Jansen, M., Potschka, H., Brandt, C., Dannhardt, G., Löscher, W. Hydantoin substituted 4,6-dichloroindole-2-car-boxylic acids as ligands with high affinity for the glycine binding site of the NMDA receptor. J Med Chem 2003, 46: 64-73.
52. Schmitz, D., Gloveli, T., Heinemann, U. Effects of losigamone on synaptic potentials and spike frequency habituation in rat entorhinal cortex and hippocampal CA1 neurones. Neurosci Lett 1995, 200: 141-3.
53. Srinivasan, J., Richens, A., Davies, J.A. The effect of losigamone (AO-33) on electrical activity and excitatory amino acid release in mouse cortical slices. Br J Pharmacol 1997, 122: 1490-4.
54. Kohr, G., Heinemann, U. Anticonvulsant effects of tetronic acid derivatives on picrotoxin induced epileptiform activity in rat hippocampal slices. Neurosci Lett 1990, 112: 43-7.
55. Willmore, L.J. Losigamone. Curr Opin Investig Drugs 2001, 2: 1763-6.
56. + current in rat hippocampal neurons. Brain Res 2001, 920: 27-31.
57. Jones, F.A., Davies, J.A. The anticonvulsant effects of the enantiomers of losigamone. Br J Pharmacol 1999, 128: 1223-8.
58. Bauer, J., Schwalen, S. Topiramate (Topamax™). Pharmacological characteristics and current use in epilepsy treatment. Nervenarzt 2000, 71: 495-501.
59. Stefan, H., Wang, Y., Kerling, F. et al. Therapeutic intensive seizure analysis (TISA) in presurgical evaluation of losigamone. Acta Neurol Scand 2001, 104: 195-201.
60. Biber, A., Dienel, A. Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. Int J Clin Pharmacol Ther 1996, 34: 6-11.
61. Tortorella, A., Halonen, T., Sahibzada, N., Gale, K. A crucial role of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype of glutamate receptors in piriform and perirhinal cortex for the initiation and propagation of limbic motor seizures. J Pharmacol Exp Ther 1997, 280: 1401-5.
62. Rogawski, M.A., Donevan, S.D. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv Neurol 1999, 79: 947-63.
63. Auberson, Y.P. Competitive AMPA antagonism: A novel mechanism for antiepileptic drugs? Drugs Fut 2001, 26: 463-71.
64. Jonas, P., Burnashev, N. Molecular mechanisms controlling calcium entry through AMPA-type glutamate receptor channels. Neuron 1995, 15: 987-90.
65. 2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron 1995, 15: 193-204.
66. 2 expression of three characteristic features of AMPA receptors. J Neurosci 1997, 17: 9393-406.
67. McBain, C.J., Dingledine, R. Heterogeneity of synaptic glutamate receptors on CA3 stratum radiatum interneurones of rat hippocampus. J Physiol 1993, 462: 373-92.
68. Zhou, F.M., Hablitz, J.J. Rapid kinetics and inward rectification of miniature EPSCs in layer I neurons of rat neocortex. J Neurophysiol 1997, 77: 2416-26.
69. 2+ permeable AMPA/kainate channels display distinct receptor immunoreactivity and are GABAergic. Neurobiol Dis 1994, 1: 43-9.
70. Kharazia, V.N., Phend, K.D., Rustioni, A., Weinberg, R.J. EM colocalization of AMPA and NMDA receptor subunits at synapses in rat cerebral cortex. Neurosci Lett 1996, 210: 37-40.
71. Herron, C.E., Lester, R.A., Coan, E.J., Collingridge, G.L. Frequency-dependent involvement of NMDA receptors in the hippocampus: A novel synaptic mechanism. Nature 1986, 322: 265-8.
72. Czuczwar, S.J., Swiader, M., Kuzniar, H., Gasior, M., Kleinrok, Z. LY300164, a novel antgonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol 1998, 359: 103-9.
73. Swiader, M., Kuzniar, H., Kleinrok, Z., Czuczwar S.J. Influence of LY300164, an AMPA/kainate receptor antagonist upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in mice. Pol J Pharmacol 2003, 55: 103-7.
74. Borowicz, K.K., Kleinrok, Z., Czuczwar, S.J. The AMPA/kainate receptor antagonist, LY300164, increases the anticonvulsant effects of diazepam. Arch Pharmacol 2000, 361: 629-35.
75. Lodge, D., Bond, A., O'Neill, M.J., Hicks, C.A., Jones, M.G. Stereoselective effects-of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies. Neuropharmacology 1996, 35: 1681-8.
76. Andrási, F. Talampanel. Drugs Fut 2001, 26: 754-6.
77. Belayev, L., Alonso, O.F., Liu, Y. et al. Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J Neurotrauma 2001, 18: 1031-8.
78. Chappell, A.S., Sander, J.W., Brodie, M.J. et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002, 58: 1680-2.
79. Kohara., A., Okada, M., Tsutsumi, R. et al. In-vitro characterization of YM872, a selective, potent and highly water-soluble α -amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J Pharm Pharmacol 1998, 50: 795-801.
80. Takahashi, M., Kohara, A., Shishikura, J. et al. YM872: A selective, potent and highly water-soluble α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist. CNS Drug Rev 2002, 8: 337-52.
81. Ohno, K., Tsutsumi, R., Matsumoto, N. et al. Functional characterization of YM928, a novel noncompetititve α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. J Pharmacol Exp Ther 2003, 303: 66-72.
82. Weiser, T., Brenner, M., Palluk, R. et al. BIIR 561 CL: A novel combined antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties. J Pharmacol Exp Ther 1999, 289: 1343-9.
83. + channels and the molecular pathogenesis of epilepsy: Implications for therapy. Trends Neurosci 2000, 23: 393-8.
84. Schroder, R.L., Jespersen, T., Christophersen, P., Strobaek, D., Jensen, B.S., Olesen, S.P. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001, 40: 888-98.
85. Nickel, B., Shandra., A., Godlevsky, L., Mazarati, A., Kupferberg, H., Szelenyi, I. Anticonvulsant activity of D-20443. Arch Pharmacol 1993, 347 (Suppl.): Abst R-142.
86. Nickel, B., Shandra, A., Godlevsky, L., Mazarati, A., Kupferberg, H., Szelenyi, I. Antiepileptic effects of a new drug: D-20443. Epilepsia 1993, 34 (Suppl. 2): Abst 95.
87. Dailey, J.W., Cheong, J.H., Ko, K.H., Adams-Curtis, L.E., Jobe, P.C. Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: Prediction of clinical response. Neurosci Lett 1995, 195: 77-80.
88. Tober, C., Rostock, A., Rundfeldt, C., Bartsch, R. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996, 303: 163-9.
89. Yonekawa, W.D., Kapetanovic, I.M., Kupferberg, H.J. The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro. Epilepsy Res 1995, 20: 137-50.
90. Rundfeldt, C., Netzer, R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000, 282: 73-6.
91. Main, M.J., Cryan, J.E., Dupere, J.R., Cox, B., Clare, J.J., Burbidge, S.A. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000, 58: 253-62.
92. Cooper, E.C. Potassium channels: How genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs. Epilepsia 2001, 42 (Suppl. 5): 49-54.
93. Blackburn-Munro, G., Jensen, B.S. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003, 460: 109-16.
94. Cheney, J.A., Weisser, J.D., Bareyre, F.M. et al. The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J Cereb Blood Flow Metab 2001, 21: 396-403.
95. Jensen, B.S. BMS-204352: A potassium channel opener developed for the treatment of stroke. CNS Drug Rev 2002, 8: 353-60.
96. Lee, J.H., Daud, A.N., Cribbs, L.L. et al. Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family. J Neurosci 1999, 19: 1912-21.
97. Fariello, R.G., Maj, R., Marrari, P., Beard, D., Algate, C., Salvati, P. Acute behavioral and EEG effects of NW-1015 on electrically-induced afterdischarge in conscious monkeys. Epilepsy Res 2000, 39: 37-46.
98. Maj, R., Fariello, R.G., Pevarello, P., Varasi, M., McArthur, R.A., Salvati, P. Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures. Epilepsia 1999, 40: 1523-8.
99. Salvati, P., Maj, R., Caccia, C. et al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther 1999, 288: 1151-9.
100. Strolin Benedetti, M.S., Marrari, P., Colombo, M. et al. The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J Pharm Pharmacol 1994, 46: 814-9.
101. Chazot, P.L. Safinamide (Newron Pharmaceuticals). Curr Opin Investig Drugs 2001, 2: 809-13.
102. Jain, K.K. An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Expert Opin Investig Drugs 2000, 9: 829-40.
103. Brunner, L.A., Harrigan, E.P., John, V.A., Powell, M.L. Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400-1200 mg. Am J Ther 1994, 1: 215-20.
104. Palhagen, S., Canger, R., Henriksen, O., van Parys, J.A., Riviere, M.E., Karolchyk, M.A. Rufinamide: A double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001, 43: 115-24.
105. + channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur J Pharmacol 2002, 438: 63-8.
106. Nehlig, A., Boehrer, A. Effects of remacemide in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsy Res 2003, 52: 253-61.
107. Meldrum, B.S. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994, 44 (11, Suppl. 8): S14-23.
108. Besag, F.M., Newton, R.E., Blakey, G.E., Dean, A.D. Safety, tolerability, and pharmacokinetics of remacemide in children. Pediatr Neurol 2001, 24: 352-6.
109. Brodie, M.J., Wroe, S.J., Dean, A.D., Holdich, T.A., Whitehead, J., Stevens, J.W. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: Comparison by sequential analysis. Epilepsy Behav 2002, 3: 140-6.
110. Leach, J.P., Marson, A.G., Hutton, J.L. Remacemide for drug-resistant localization related epilepsy. Cochrane Database Syst Rev 2002, 4: CD001900.
111. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 1999, 22: 220-5.
112. Fatope, M.O. Soretolide (Laboratoires Biocodex). Curr Opin Investig Drugs 2001, 2: 824-7.
113. Maurizis, J.C., Madelmont, J.C., Rapp, M. et al. Disposition and metabolism of 2,6-dimethylbenzamide N-(5-methyl-3-isoxazolyl) (D2916) in male and female rats. Drug Metab Dispos 1997, 25: 33-9.
114. Upton, N., Blackburn, T.P., Campbell, C.A. et al. Profile of SB-204269, a mechanistically novel anticonvulsant drug, in rat models of focal and generalized epileptic seizures. Br J Pharmacol 1997, 121: 1679-86.
115. Herdon, H., Jerman, J., Stean, T., Chan, W., Middlemiss, D., Upton, N. The novel anticonvulsant SB 204269 binds to a stereospecific site in the mouse brain. Eur J Pharmacol 1996, 314: R7-8.
116. Caeser, M., Evans, M.L., Benham, C.D. Lack of effect of the novel anticonvulsant SB-204269 on voltage-dependent currents in neurones cultured from rat hippocampus. Neurosci Lett 1999, 271: 57-60.
117. Parsons, A.A., Bingham, S., Raval, P., Read, S., Thompson, M., Upton, N. Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol 2001, 132: 1549-57.
118. Hadad, S., Bialer, M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm Drug Dispos 1997, 18: 557-66.
119. Isoherranen, N., Woodhead, J.H., White, H.S., Bialer, M. Anticonvulsant profile of valrocemide (TV1901): A new antiepileptic drug. Epilepsia 2001, 42: 831-6.
120. Bialer, M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release 1999, 62: 187-92.
121. Isoherranen, N., Yagen, B., Bialer, M. New CNS-active drugs which are second-generation valproic acid: Can they lead to the development of a magic bullet? Curr Opin Neurol 2003, 16: 203-11.
122. Labiner, D.M. DP-VPA (D-Pharm). Curr Opin Investig Drugs 2002, 3: 921-3.
123. NaP in cortical neurons. Neuroreport 2002, 13: 1167-70.
124. Lang, S. The role of peripheral benzodiazepine receptors (PBRs) in CNS pathophysiology. Curr Med Chem 2002, 9: 1411-5.
125. Veenman, L., Leschiner, S., Spanier, I., Weisinger, G., Weizman, A., Gavish, M. PK 11195 attenuates kainic acid-induced seizures and alterations in peripheral-type benzodiazepine receptor (PBR) protein components in the rat brain. J Neurochem 2002, 80: 917-27.
126. Vezzani, A., Sperk, G., Colmers, W.F. Neuropeptide Y: Emerging evidence for a functional role in seizure modulation. TiNS 1999, 22: 25-30.
127. Mazarati, A., Langel, U., Bartfai, T. Galanin: An endogenous anticonvulsant? Neuroscientist 2001, 7: 506-17.
128. 2 and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats. Neuroscience 1995, 65: 1087-97.
129. Saar, K., Mazarati, A.M., Mahlapuu, R. et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 2002, 99: 7136-41.
130. 1 receptor antagonist: BIBP3226. Eur J Pharmacol 1994, 271: R11-R13.
131. Scheffer, G.L., Scheper, R.J. Drug-resistance molecules: Lessons from oncology. In: Mechanisms of Drug Resistance in Epilepsy: Lessons from Oncology. Novartis Foundation Symposium. John Wiley & Sons: Chichester 2002, 19-31.
132. Cordon-Cardo, C., O'Brien, J.P., Casals, D. et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86: 695-8.
133. Fromm, M.F P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000, 38: 69-74.
134. Sisodiya, S.M., Lin, W.R., Harding, B.N., Squier, M.V., Thom, M. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125: 22-31.
135. Abbot, N.J., Khan, E.U., Rollinson, C.M.S. et al. Drug-resistance in epilepsy: The role of the blood-brain barrier., In: Mechanisms of Drug Resistance in Epilepsy: Lessons from Oncology. Novartis Foundation Symposium. John Wiley & Sons: Chichester 2002, 38-47.
136. Lemaire, M., Bruelisauer, A., Guntz, P., Sato, H. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 1996, 38: 481-6.
137. Dantzig, A.H., Shepard, R.L., Law, K.L. et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999, 290: 854-62.